Strides Pharma Science Limited

BSE: 532531 NSE: STAR
Strides Pharma Science Limited - pharma in Thane, Maharashtra, India. FY 2026 financials & compliance.
CIN L24230MH1990PLC057062 Incorporated 28 June 1990 ROC Mumbai HQ Thane, Maharashtra, India
Active Listed - NSE: STAR · BSE: 532531 Public Limited Company pharma
Data last updated
Market Cap
₹11,087 Cr
STAR · NSE
Share Price
₹1,184.90
-1.49% today
Revenue
₹4,859 Cr
FY 2025-26 · +4.1% YoY
EBITDA
₹898 Cr
Margin 18.5%
Net Profit
₹566 Cr
FY 2025-26 · -83.9% YoY
P/E (TTM)
19.5x
P/B 3.6x
ROE
20.3%
ROCE 17.7%
Debt / Equity
0.64
Interest cover 25.6x

About Strides Pharma Science Limited

Data last updated: 25 September 2026

Strides Pharma Science Limited is a public limited company based in Thane, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 28 June 1990, the company has been in operation for over 36 years.

Registered with ROC Mumbai under CIN L24230MH1990PLC057062. Listed on BSE: 532531 and NSE: STAR.

Capital: an authorised share capital of ₹218.37 Cr and a paid-up capital of ₹92.17 Cr. Formerly known as Strides Pharma Sciences Limited and Strides Shasun Limited. It is led by directors including Homi Rustam Khusrokhan and Venkata Seetharama Raju Pakalapati.

Last AGM: 14 August 2026. Financial statements filed for year ended 31 March 2026. Office: Sector 30, Thane, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹4,858.68 Cr, a growth of 6.43% compared to the previous year. The net worth stands at ₹3,107.56 Cr (up 21.78% YoY). Total assets are valued at ₹5,064.9 Cr (up 10.23% YoY).

The company has a workforce of approximately 2,152 employees as per the latest available data. Its group structure includes 3 subsidiaries.

The company is associated with 1 brand - Strides Pharma Science. As per MCA filings, the company has open charges of ₹1,905.26 Cr and satisfied charges of ₹11,468 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website strides.com.

Company Details of Strides Pharma Science Limited
CIN L24230MH1990PLC057062
Registration Number 057062
Incorporation Date 28 June 1990
ROC Mumbai
Listing Status Listed (BSE: 532531, NSE: STAR)
Company Status Active
Date of Last AGM 14 August 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Key People
Badree Komandur Managing Director Venkata Seetharama Raju Pakalapati Whole-Time Director Vikesh Kumar Cfo
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    strides.com
  • Social Media
  • Registered Address
    Cyber One Unit No. 902 Sector 30A, Plot No – 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703
  • Industry
    Pharma, Drug Formulation & Development
Company report
Strides Pharma Science Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Strides Pharma Science Limited report

Financials, compliance, directors, charges, ownership and filings for Strides Pharma Science Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Strides Pharma Science Limited

Strides Pharma Science Limited has undergone 7 name changes throughout its history. The current legal name is Strides Pharma Science Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Strides Pharma Science Limited Current
Strides Pharma Sciences Limited Previous
Strides Shasun Limited Previous
Strides Arcolab Limited Previous
Strides Pharma Limited Previous
Strides Pharmaceuticals Limited Previous
Strides Pharmaceuticals Private Limited Previous
Strides Limited Previous

Associated Brands with Strides Pharma Science Limited

Strides Pharma Science Limited operates one associated brand: Strides Pharma Science. These brands represent Strides Pharma Science Limited's diversified market presence and brand portfolio.

Brand Description Website
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured. strides.com

Business Activity of Strides Pharma Science Limited

Strides Pharma Science Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Strides Pharma Science Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Strides Pharma Science Limited

Strides Pharma Science Limited is audited by B S R & Co. LLP for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
B S R & Co. LLP Locked Locked Locked
Premium access

Complete auditor history for Strides Pharma Science Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors and KMP of Strides Pharma Science Limited

Strides Pharma Science Limited currently reports 9 directors and 2 key managerial personnel. 19 former directors have served the organization.

Current Directors and KMP
Name Designation Appointment Date Tenure Status
Homi Rustam Khusrokhan
Also directs: Neuland Laboratories Ltd., The Anglo Scottish Education Society
Director 18 May 2017 9 Years 4 Months Current
Vikesh Kumar Cfo 01 Jun 2024 2 Years 3 Months Current
Venkata Seetharama Raju Pakalapati
Also directs: Sunspire Life Sciences Private Limited
Whole-Time Director 01 Jun 2026 0 Years 3 Months Current
Manjula Ramamurthy Company Secretary 03 Feb 2017 9 Years 7 Months Current
Badree Komandur Managing Director 18 May 2017 9 Years 4 Months Current
Subir Chakraborty
Also directs: Ifb Industries Ltd
Director 01 Jun 2024 2 Years 3 Months Current
Showing 6 of 11 current directors and KMP. View all directors and KMP

Financials of Strides Pharma Science Limited FY 2025-26 filings available

Strides Pharma Science Limited reported revenue of ₹4,858.68 Cr (up 6.43% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹4,859 Cr
+6.4% YoY
EBITDA
₹898 Cr
+18.2% YoY
Profit After Tax
₹566 Cr
-83.9% YoY
Net Worth
₹3,108 Cr
+21.8% YoY
Total Assets
₹5,065 Cr
+10.2% YoY
Total Debt
₹1,758 Cr
-6.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,8594,5653,8903,6883,0703,3162,752
Revenue growth+4.1%+7.1%-4.0%+5.7%+21.9%+13.2%+24.1%
EBITDA898760339(10.19)(431)443214
EBITDA margin+18.5%+16.7%+8.7%-0.3%-14.0%+13.4%+7.8%
Profit before tax6693,675(65.21)(268)(653)28941.92
Net profit5663,521149(190)(228)22762.43
Net profit margin+11.7%+77.1%+3.8%-5.1%-7.4%+6.8%+2.3%
EPS (₹)60.34389.90(7.68)(22.44)(51.25)29.934.06
Balance sheet
Total assets5,0654,5954,6945,2905,5315,4864,963
Net worth3,1082,5522,1262,2122,3592,7772,527
Total debt1,7581,8802,5173,0303,0252,3482,235
Cash & bank213137191316187180237
Net working capital1,8721,6951,7581,8881,9531,2351,085
Cash flow
Cash from operations70368470144.41(258)481205
Cash from investing(173)(90.25)(150)302(119)(522)1,321
Cash from financing(453)(643)(693)(214)421(15.80)(1,709)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,2651,3231,1951,2211,1201,1901,1541,167
Revenue growth (YoY)+13.0%+11.2%+3.6%+4.6%+6.2%+14.1%+14.7%+16.8%
Other income68.099.5810727.148.6815.116.5728.41
EBITDA228233233222210190208180
EBITDA margin+18.1%+17.6%+19.5%+18.2%+18.7%+16.0%+18.0%+15.4%
Depreciation56.4053.2550.6249.6448.8948.8648.4248.45
Interest40.5641.5843.3846.1347.4650.3252.1873.82
Profit before tax20014824515312210611486.21
Tax34.1318.7737.3621.5916.4520.7623.8013.94
Net profit16512920813210685.6290.0672.27
EPS (₹)17.0213.7721.9213.8410.818.929.557.80
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,1802,1391,8661,8541,9791,8581,692
Revenue growth+1.0%+9.1%-2.8%-6.9%+12.0%+14.2%+5.8%
EBITDA28526214583.4876.62159204
EBITDA margin+13.1%+12.3%+7.8%+4.5%+3.9%+8.6%+12.1%
Profit before tax2032,90545.88(64.75)21.50112136
Net profit73.562,88650.0721.0117674.98117
Net profit margin+3.4%+134.9%+2.7%+1.1%+8.9%+4.0%+6.9%
EPS (₹)19.92313.164.850.5220.078.7213.43
Balance sheet
Total assets4,5484,4485,2634,9034,7254,3774,085
Net worth3,2843,1933,5283,4553,4073,2483,159
Total debt1,1841,2021,6881,4141,284917902
Cash & bank40.6830.5011585.5814.4573.04110
Net working capital1,5261,5621,7721,4091,266899804
Cash flow
Cash from operations278421(14.01)242(283)283138
Cash from investing(69.07)(138)(68.69)(183)18.78(276)62.83
Cash from financing(199)(370)93.3410.82251(48.64)(204)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue583606554522499556551520
Revenue growth (YoY)+16.9%+9.0%+0.5%+0.5%-14.9%-7.8%+45.1%-6.0%
Other income77.883.9710314.091.7612.122.4323.55
Total expenses522531472460431488477464
EBITDA61.1274.4081.2062.2267.2367.9374.0855.36
EBITDA margin+10.5%+12.3%+14.7%+11.9%+13.5%+12.2%+13.4%+10.7%
Depreciation25.7325.1922.4021.5122.1422.3720.9220.70
Interest28.5126.6627.2529.4130.4529.3634.2141.83
Profit before tax84.7626.5213525.3916.4028.3221.3816.38
Tax11.8310.1512.91(6.65)3.0512.196.44(0.87)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,2651,3231,1951,2211,1201,1901,1541,167
Revenue growth (YoY)+13.0%+11.2%+3.6%+4.6%+6.2%+14.1%+14.7%+16.8%
Other income68.099.5810727.148.6815.116.5728.41
EBITDA228233233222210190208180
EBITDA margin+18.1%+17.6%+19.5%+18.2%+18.7%+16.0%+18.0%+15.4%
Depreciation56.4053.2550.6249.6448.8948.8648.4248.45
Interest40.5641.5843.3846.1347.4650.3252.1873.82
Profit before tax20014824515312210611486.21
Tax34.1318.7737.3621.5916.4520.7623.8013.94
Net profit16512920813210685.6290.0672.27
EPS (₹)17.0213.7721.9213.8410.818.929.557.80
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,8594,5653,8903,6883,0703,3162,752
Revenue growth+4.1%+7.1%-4.0%+5.7%+21.9%+13.2%+24.1%
Other income1513,35689.85247188203157
Total expenses3,9603,8053,5513,6993,5012,8732,538
Employee cost929863737732647550443
EBITDA898760339(10.19)(431)443214
EBITDA margin+18.5%+16.7%+8.7%-0.3%-14.0%+13.4%+7.8%
Depreciation202192214243233206174
Interest179249280261177150156
Profit before tax6693,675(65.21)(268)(653)28941.92
Tax94.1777.5229.11(55.30)(178)31.6511.33
Net profit5663,521149(190)(228)22762.43
Net profit margin+11.7%+77.1%+3.8%-5.1%-7.4%+6.8%+2.3%
EPS (₹)60.34389.90(7.68)(22.44)(51.25)29.934.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital92.1792.1691.9090.3089.7989.6889.57
Reserves & surplus3,0152,4602,0342,1052,2692,6872,438
Shareholders' funds (net worth)3,1082,5522,1262,2122,3592,7772,527
Minority interest41.7734.63(53.86)(39.38)24.0937.3467.24
Secured loans1,4991,6502,2412,5682,1092,0331,955
Unsecured loans259229276461916316279
Total debt1,7581,8802,5173,0303,0252,3482,235
Total liabilities5,0654,5954,6945,2905,5315,4864,963
Assets
Gross block3,3042,9112,8873,3393,2462,9382,631
Net block2,1011,8991,8652,3112,3472,2192,099
Capital work in progress447207162151291447413
Investments291409303490540697549
Inventories1,6351,2781,1261,1471,1741,201783
Sundry debtors1,2891,2031,1421,2991,2071,107932
Cash & bank balances213137191316187180237
Loans & advances476412404431793230302
Total current assets3,6133,0292,8633,1933,3622,7182,253
Total current liabilities1,7421,3351,1061,3041,4091,4831,168
Net working capital1,8721,6951,7581,8881,9531,2351,085
Total assets5,0654,5954,6945,2905,5315,4864,963
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash113161304171126182366
Net cash from operating activities70368470144.41(258)481205
Net cash from investing activities(173)(90.25)(150)302(119)(522)1,321
Net cash from financing activities(453)(643)(693)(214)421(15.80)(1,709)
Net change in cash76.13(48.46)(142)13344.90(56.40)(184)
Closing cash213137191316187180237
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.4%+17.4%+5.5%+20.1%-7.4%+20.5%+26.3%
EBITDA growth+18.2%+124.5%+9998.0%+97.6%-+107.0%+61.5%
PBT growth-81.8%+9998.0%+75.6%+59.0%-+590.3%-86.2%
Net income growth-83.9%+2269.5%+9998.0%+16.8%-+263.1%-78.9%
Revenue CAGR (3Y)+9.6%+14.1%+5.5%+10.3%+12.1%+5.2%-0.0%
EBITDA CAGR (3Y)---8.5%--+8.1%-23.4%
Profitability & leverage
Net income margin+11.8%+78.8%-2.4%-5.8%-15.5%+7.8%+1.1%
Return on capital employed+17.7%+14.3%0.0%0.0%-4.4%+7.3%+5.1%
Return on net worth+20.3%+150.7%0.0%0.0%-9.4%+8.1%+2.2%
Debt / equity0.640.941.281.321.050.861.05
Long-term debt / equity0.220.290.480.520.410.370.51
Interest cover25.6543.80223.89-103.04-26.6363.46387.65
Efficiency & per share
Fixed asset turnover1.561.571.251.120.991.190.81
Inventory turnover3.343.803.423.182.593.343.32
Debtors turnover3.903.893.192.942.653.252.87
EPS (₹)60.34389.90(7.68)(22.44)(51.25)29.934.06
Dividend per share (₹)5.004.002.501.500.002.5014.00
Book value per share (₹)337.14276.88231.28243.09262.70309.62282.19
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue583606554522499556551520
Revenue growth (YoY)+16.9%+9.0%+0.5%+0.5%-14.9%-7.8%+45.1%-6.0%
Other income77.883.9710314.091.7612.122.4323.55
Total expenses522531472460431488477464
EBITDA61.1274.4081.2062.2267.2367.9374.0855.36
EBITDA margin+10.5%+12.3%+14.7%+11.9%+13.5%+12.2%+13.4%+10.7%
Depreciation25.7325.1922.4021.5122.1422.3720.9220.70
Interest28.5126.6627.2529.4130.4529.3634.2141.83
Profit before tax84.7626.5213525.3916.4028.3221.3816.38
Tax11.8310.1512.91(6.65)3.0512.196.44(0.87)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,1802,1391,8661,8541,9791,8581,692
Revenue growth+1.0%+9.1%-2.8%-6.9%+12.0%+14.2%+5.8%
Other income1232,87312884.0712311793.07
Total expenses1,8951,8771,7211,7711,9021,6981,487
Employee cost382378349267272273230
EBITDA28526214583.4876.62159204
EBITDA margin+13.1%+12.3%+7.8%+4.5%+3.9%+8.6%+12.1%
Depreciation91.2484.6187.4193.6210499.3494.24
Interest11414613913974.2465.3466.84
Profit before tax2032,90545.88(64.75)21.50112136
Tax19.4718.931.34(69.44)(159)33.3916.17
Net profit73.562,88650.0721.0117674.98117
Net profit margin+3.4%+134.9%+2.7%+1.1%+8.9%+4.0%+6.9%
EPS (₹)19.92313.164.850.5220.078.7213.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital92.1792.1691.9090.3089.7989.6889.57
Reserves & surplus3,1913,1013,4363,3483,3163,1583,069
Shareholders' funds (net worth)3,2843,1933,5283,4553,4073,2483,159
Secured loans9951,0241,5271,2541,122792846
Unsecured loans19017816116016212555.18
Total debt1,1841,2021,6881,4141,284917902
Total liabilities4,5484,4485,2634,9034,7254,3774,085
Assets
Gross block1,5801,4931,4601,1961,1421,0991,020
Net block785767747597617644651
Capital work in progress18110610755.3855.72111112
Investments1,8681,8482,3642,4922,4002,3952,171
Inventories580432498491513689463
Sundry debtors1,5211,4531,5651,3081,296822656
Cash & bank balances40.6830.5011585.5814.4573.04110
Loans & advances231230233242151160167
Total current assets2,3742,1462,4112,1261,9751,7441,396
Total current liabilities847583639717709845592
Net working capital1,5261,5621,7721,4091,266899804
Total assets4,5484,4485,2634,9034,7254,3774,085
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash6.3392.7582.1112.1225.3066.8269.91
Net cash from operating activities278421(14.01)242(283)283138
Net cash from investing activities(69.07)(138)(68.69)(183)18.78(276)62.83
Net cash from financing activities(199)(370)93.3410.82251(48.64)(204)
Net change in cash9.84(86.42)10.6569.98(13.18)(41.52)(3.09)
Closing cash40.6830.5011585.5814.4573.04110
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1.9%+14.7%+0.6%-6.3%+6.5%+9.8%+10.1%
EBITDA growth+8.6%+80.8%+73.9%+9.0%-51.9%-22.1%+55.5%
PBT growth-93.0%+6232.0%+9998.0%--80.7%-18.2%+25.2%
Net income growth-97.5%+5664.6%+138.3%-88.1%+134.7%-35.8%+9.7%
Revenue CAGR (3Y)+5.5%+2.6%+0.2%+3.1%+8.8%+8.1%+7.0%
EBITDA CAGR (3Y)+50.6%+50.7%-3.0%-25.8%-16.5%-1.0%+23.5%
Profitability & leverage
Net income margin+8.4%+134.9%+2.4%+0.3%+9.1%+4.2%+7.1%
Return on capital employed+4.8%+4.6%+2.4%+1.9%+1.9%+4.2%+5.0%
Return on net worth+2.3%+85.9%+1.4%+0.6%+5.3%+2.4%+3.8%
Debt / equity0.370.430.440.390.330.280.27
Long-term debt / equity0.050.060.080.070.050.030.01
Interest cover58.7082.06241.48-1,367.65-267.53109.1260.64
Efficiency & per share
Fixed asset turnover1.421.451.411.591.771.751.82
Inventory turnover4.314.603.773.693.293.233.61
Debtors turnover1.471.421.301.421.872.512.73
EPS (₹)19.92313.164.850.5220.078.7213.43
Dividend per share (₹)5.004.002.501.500.002.5014.00
Book value per share (₹)356.23346.42383.84380.71379.36362.18352.68
Want more history and ratios?
You're viewing the latest exchange-filed financials for Strides Pharma Science Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Strides Pharma Science Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 27.90%, foreign institutional investors hold 28.40%, domestic institutional investors hold 15.40%, retail and other public shareholders hold 28.30% of Strides Pharma Science Limited.

Promoters: 27.90%DII (Domestic Institutional): 15.40%FII (Foreign Institutional): 28.40%Retail & Others: 28.30%
Jun 2026
QUARTER
27.90% Promoters
15.40% DII (Domestic Institutional)
28.40% FII (Foreign Institutional)
28.30% Retail & Others
Promoter holding - history
Now 27.90% · Jun 2026High 27.90% · Sep 2025Low 27.90% · Sep 2025
26%26.8%27.5%28.3%29%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 27.90%Dec 2025: 27.90%Mar 2026: 27.90%Jun 2026: 27.90%27.90%27.90%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters27.90%27.90%27.90%27.90%
Public72.10%72.10%72.10%72.10%

Group Structure of Strides Pharma Science Limited

Strides Pharma Science Limited has 3 subsidiary companies and 3 associated companies. This group structure data is as of FY 2023. The corporate group structure reflects Strides Pharma Science Limited's business expansion strategy and organizational complexity.

3
Subsidiary companies
3
Associated companies
Key Subsidiaries
Company Name CIN Shares Held

Showing major subsidiaries. Total: 3.

Charges & Borrowings of Strides Pharma Science Limited

Open charges
₹1,905.26 Cr
Satisfied charges
₹11,468 Cr
Breakdown by lending institutions
Others₹1,904.62 Cr
Hdfc Bank Limited₹0.64 Cr
Latest charge details
DateLenderAmountStatus
24 Jul 2026 Others ₹75 Cr Open
20 Oct 2023 Hdfc Bank Limited ₹64.39 Lakh Open
19 Jul 2016 Others ₹1,829.62 Cr Open
27 Mar 2025 Others ₹100 Cr Satisfied
10 Feb 2025 Karnataka Bank Ltd. ₹100 Cr Satisfied

Total charge records: 275 View all charges

Employees and EPFO Compliance at Strides Pharma Science Limited

Strides Pharma Science Limited has a workforce of 2,152 employees as of Nov 19, 2024.

Employee count
2,152
Active EPFO establishments
3
Employee growth
1.94%
Premium access

Employee and EPFO history for Strides Pharma Science Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Strides Pharma Science Limited

Premium access

GST registrations and filing compliance for Strides Pharma Science Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Strides Pharma Science Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Strides Pharma Science Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Strides Pharma Science Limited

Premium access

MSME payment history for Strides Pharma Science Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Strides Pharma Science Limited

Premium access

Corporate group structure for Strides Pharma Science Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Strides Pharma Science Limited

Premium access

MCA filings and documents for Strides Pharma Science Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Strides Pharma Science Limited

Activity
14 Aug 2026
Strides Pharma Science Limited last Annual general meeting of members was held on 14 Aug 2026 as per latest MCA records.
Charges
24 Jul 2026
A charge with Others amounted to Rs. 75.00 Cr with Charge ID 101356437 was registered on 24 Jul 2026.
Directors
01 Jun 2026
Venkata Seetharama Raju Pakalapati was appointed as a Whole-time director on 01 Jun 2026 & has been associated with this company since 3 months 27 days.
Charges
15 May 2026
A charge with Others of Rs. 1,829.62 Cr registered on 19 Jul 2016 with Charge ID 100062848 was modified on 15 May 2026.
Activity
31 Mar 2026
Strides Pharma Science Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai Ii.
Charges
09 Nov 2025
A charge registered on 03 Nov 2020 via Charge ID 100389968 with Hdfc Bank Limited was fully satisfied on 09 Nov 2025.

Recent News on Strides Pharma Science Limited

Teva Names R. Ananth CEO for API Business
08 Nov 2023 · Contract Pharma

Frequently Asked Questions about Strides Pharma Science Limited

Strides Pharma Science Limited is an active public limited company in the pharma sector based in Thane, Maharashtra, India. It was incorporated on 28 June 1990 (36+ years old) and is registered under CIN L24230MH1990PLC057062. Listed on BSE: 532531 and NSE: STAR. The company has 2,152 employees.

Strides Pharma Science Limited reported revenue of ₹4,858.68 Cr for FY 2025-26 (up 6.43% YoY) based on consolidated financials.

The current directors and KMP of Strides Pharma Science Limited are:

The primary industry of Strides Pharma Science Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Strides Pharma Science Limited is listed on both BSE (code: 532531) and NSE (symbol: STAR).

Strides Pharma Science Limited can be reached at the registered office: Cyber One Unit No. 902 Sector 30A, Plot No – 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703, or through the website strides.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available